Page 129 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

References
1. Henricks LM, Kienhuis E, de Man FM, et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low dose capecitabine. JCO Precis Oncol. 2017.
2. Henricks LM, Siemerink EJM, Rosing H, et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer. 2018;142(2):424-430.
3. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other 4 fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta- analysis. J Clin Oncol. 2014;32(10):1031-1039.
4. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer letters. 2007;249(2):271-282.
5. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-2904.
6. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the Dihydropyrimidine dehydrogenase (DPD) gene within the 5 ‘-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clinical Cancer Research. 2001;7(9):2832-2839.
7. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5(8):2006-2011.
8. SPC Fluorouracil PCH 15 October 2012.
9. SPC Efudix (fluorouracil) crème 07 September 2016.
10. SPC Xeloda (capecitabine) 26 July 2016.
11. SPC Fluorouracil 29 July 2016 (USA).
12. SPC Xeloda (capecitabine) 14 December 2016 (USA)
13. SPC Carac (fluorouracil) cream 16 December 2003 (USA).
14. Lunenburg CATC, van Staveren MC, Gelderblom H, Guchelaar HJ, Swen JJ. Evaluation of clinical
implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated
patients. Pharmacogenomics. 2016;17(7):721-729.
15. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant
colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12).
16. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-
1424.
17. Kodali S, Bathini V, Rava P, Tipirneni E. Capecitabine-Induced Severe Toxicity Secondary to DPD
Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. J Gastrointest Cancer. 2016.
18. Meulendijks D, Henricks LM, van Kuilenburg AB, et al. Patients homozygous for DPYD c.1129- 5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated
with fluoropyrimidines. Cancer Chemother Pharmacol. 2016;78(4):875-880.
19. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize
Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
127
Supplement